Revumenib Shows Promise Across Menin-Sensitive AML Subtypes and Could Shift Treatment Paradigms: With Naval Daver, MD

Welcome to OncLive On Air®! I’m your host today, Jax DiEugenio.

In today’s episode, we spoke with Naval Daver, MD, about the evolving role of menin inhibition in acute myeloid leukemia (AML) and emerging data with revumenib (Revuforj) presented across ongoing clinical trials. Dr Daver is a professor in the Department of Leukemia and director of the Leukemia Research Alliance Program at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Daver discussed findings from the phase 1 AUGMENT-101 trial (NCT04065399), which evaluated revumenib in patients with relapsed/refractory AML harboring NPM1 mutations. Among this cohort, revumenib demonstrated a composite complete remission (CRc) rate of approximately 25% and an overall response rate (ORR) of about 50%. He noted that patients with relapsed NPM1-mutated AML typically have poor outcomes with standard salvage therapies, highlighting the need for targeted approaches in this setting.

He also reviewed the potential for menin inhibition in NUP98-rearranged AML, where clinical responses have been observed but appear less durable and more variable. Dr Daver emphasized the differential sensitivity of menin-targeted agents across molecular subtypes, with highest activity seen in KMT2A-rearranged AML, followed by NPM1, and lower activity in NUP98 fusions, explaining how ongoing efforts are investigating the use of revumenib in combination with hypomethylating agents (HMAs) and venetoclax in both salvage and frontline settings.

____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by AbbVie. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.